SYS6020 injection

BIOLOGICAL2 trials

Sponsors

CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Tongji Hospital

Conditions

Multiple SclerosisMyasthenia Gravis

Phase 1

A Study to Evaluate the Safety and Preliminary Efficacy of SYS6020 CAR T-cells in Patients With Refractory Generalized Myasthenia Gravis

RecruitingNCT06688435

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Myasthenia Gravis

Start: 2025-03-04End: 2033-05-01Target: 60Updated: 2026-08-12

Phase Ib/II Study of SYS6020 in Relapsing/Refractory Multiple Sclerosis

Not yet recruitingNCT07756268

Tongji HospitalMultiple Sclerosis

Start: 2026-09-16End: 2029-02-07Target: 25Updated: 2026-08-10